Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 18

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 18
---
 1934, as amended, or the Exchange Act. In our capacity as a foreign private issuer, we are exempt from certain rules under the Exchange Act that would otherwise apply if we were a company incorporated in the United States, including:

| · | the requirement to file periodic reports and financial statements with the SEC as frequently or as promptly 
 as United States companies with securities registered under the Exchange Act;                               |

| · | the requirement to file financial statements in accordance with accounting principles generally accepted 
 in the United States, or U.S. GAAP;                                                                      |

| · | the proxy rules, which impose certain disclosure and procedural requirements for proxy solicitations; 
 and                                                                                                   |

| · | the requirement to comply with Regulation FD, which imposes certain restrictions on the selective disclosure 
 of material information.                                                                                     |

In addition, our officers, directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our Ordinary Shares. Accordingly, an investor may receive less information about us than it would receive about a public company incorporated in the United States. Additionally, we elect to follow certain home country corporate governance practices instead of those otherwise required under the listing rules of NASDAQ. Additional Information For additional information related to our business and operations, please refer to the reports incorporated herein by reference, including our Annual Report on Form 20-F for the year ended December 31, 2024, as filed with the SEC on April 11, 2025, and our Reports on Form 6-K, as filed with the SEC, as described in the section titled “ Incorporation of Certain Information by Reference.”

| 9 |

The Offering The following summary contains basic terms about this offering and the securities and is not intended to be complete. It may not contain all of the information that is important to you. You should read the more detailed information contained in this prospectus, including but not limited to, the risk factors beginning on page 14. For a more complete description of the terms of the securities, see the section of this prospectus entitled “Description of the Securities.”

| Securities offered by us |     | Up to 4,422,604 Units, each Unit consisting of one Depositary Share                                                                    
 and two Series L Warrants, each to purchase one Depositary Share.                                                                      
 This prospectus also relates to the offering of the Depositary Shares                                                                  
 issuable upon exercise of the